Alterity Therapeutics
ATHE
10 hedge funds and large institutions have $141K invested in Alterity Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 10 → 10 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
27% less capital invested
Capital invested by funds: $194K → $141K (-$52.9K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$37.5K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$35.7K |
| 3 |
Morgan Stanley
New York
|
-$7.22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $87.6K | -$7.22K | -3,590 | -7% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $42K | +$46.9K | +23,311 | New |
|
|
TLCM
3
Twin Lakes Capital Management
Redwood Shores,
California
| $10.7K | – | – | – |
|
|
PCA
4
Providence Capital Advisors
Charlotte,
North Carolina
| $362 | – | – | – |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $145 | – | – | – |
|
|
SWM
6
Sugarloaf Wealth Management
Duluth,
Georgia
| $60 | – | – | – |
|
|
CA
7
CoreCap Advisors
Southfield,
Michigan
| $38 | – | – | – |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| $11 | – | – | – |
|
|
CAS
9
Coppell Advisory Solutions
Coppell,
Texas
| $9 | +$10 | +5 | New |
|
10
UBS Group
Zurich,
Switzerland
| $4 | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$37.5K | -18,279 | Closed |
|
|
XT
12
XTX Topco
George Town,
Cayman Islands
| – | -$35.7K | -17,425 | Closed |
|
ATHE Hedge Fund Activity: Q2 2024 in Review
10 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2024, worth a combined $141K — down 27% from $194K a quarter earlier.
Fund positioning in ATHE was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $46.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $37.5K sold.
- 10 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $141K of Alterity Therapeutics stock for Q2 2024, down 27% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Alterity Therapeutics buyer in Q2 2024 was Susquehanna International Group, an estimated $46.9K added.
- The largest Alterity Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $37.5K sold.
Based on aggregated 13F filings for Q2 2024.